One reason for the potential discrepancy is that LME prices may be affected more by financial flows, while the scrapside is not influenced as much by speculative money, he suggested.
Pfizer's share price plunged after higher-than-expected mortality and side effects reported during a clinical trial led it to scrap a drug it had been developing since 1992.